Compare ARK Genomic Revolution ETF (ARKG) vs The Coca-Cola Co K (KO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs The Coca-Cola Co K — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while The Coca-Cola Co K trades at $83.86 (market cap $359.21B). The key difference: The Coca-Cola Co K pays a 2.54% dividend while ARK Genomic Revolution ETF pays none, and The Coca-Cola Co K is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | KO | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $84.14 |
52-Week Low | $23.09 | $65.67 |
Market Cap | — | $359.21B |
Volume | — | 14,630,257 |
Enterprise Value | — | $389.28B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Coca-Cola (KO) trades at $83.49, up 1.04% today, with a bullish technical signal from moving averages and strong analyst support. The company reported consistent earnings beats in recent quarters and maintains robust profitability with a 27.8% net income margin. Recent news highlights institutional buying and stable demand trends, though regional divergences exist.
The outlook is positive with a consensus price target of $89, offering ~6.6% upside. Key risks include high valuation multiples and macroeconomic sensitivity. The stock remains a core holding for dividend growth, supported by 64 consecutive years of dividend increases and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
